INT30526

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1985
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 15
Total Number 17
Disease Relevance 8.15
Pain Relevance 8.19

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleolus (PTAFR) plasma membrane (PTAFR) nucleus (PTAFR)
signal transducer activity (PTAFR)
Anatomy Link Frequency
platelet 3
erythrocytes 1
PTAFR (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 105 100.00 Very High Very High Very High
substance P 81 100.00 Very High Very High Very High
interstitial cystitis 8 99.92 Very High Very High Very High
Inflammation 198 99.60 Very High Very High Very High
diclofenac 4 99.12 Very High Very High Very High
cINOD 18 98.88 Very High Very High Very High
Multiple sclerosis 82 98.54 Very High Very High Very High
Inflammatory mediators 48 97.76 Very High Very High Very High
bradykinin 30 97.40 Very High Very High Very High
cytokine 89 95.04 Very High Very High Very High
Disease Link Frequency Relevance Heat
Wheal 26 100.00 Very High Very High Very High
Interstitial Cystitis 8 99.92 Very High Very High Very High
INFLAMMATION 240 99.60 Very High Very High Very High
Neonatal Necrotizing Enterocolitis 34 99.16 Very High Very High Very High
Multiple Sclerosis 93 98.54 Very High Very High Very High
Gastroesophageal Reflux Disease 36 96.16 Very High Very High Very High
Inflammatory Bowel Disease 68 95.56 Very High Very High Very High
Cv General 4 Under Development 1 95.48 Very High Very High Very High
Disease 62 94.40 High High
Ulcers 1 93.56 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The remaining imidazolines: xylometazoline and naphazoline effectively inhibit the platelet receptor in a non-competitive manner.
Negative_regulation (inhibit) of platelet receptor in platelet
1) Confidence 0.58 Published 1985 Journal Thromb. Haemost. Section Abstract Doc Link 2868542 Disease Relevance 0 Pain Relevance 0.23
Doxepin significantly reduced both weal and flare responses to PAF (mean reduction 43 and 68%, respectively, at higher doses of PAF).
Negative_regulation (reduction) of PAF associated with wheal
2) Confidence 0.58 Published 1996 Journal Clin. Exp. Dermatol. Section Abstract Doc Link 8689766 Disease Relevance 0.76 Pain Relevance 0.63
Among the inhibitors tested, methyl arachidonyl fluorophosphonate (MAFP) was found to be a potent inhibitor of PAF-acetylhydrolase activity.
Negative_regulation (inhibitor) of PAF
3) Confidence 0.51 Published 2005 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 15937147 Disease Relevance 0.62 Pain Relevance 0.46
Terfenadine significantly reduced weal and flare responses to PAF (mean reduction 53 and 73%, respectively) and flare responses to BK (mean reduction 78%) but had no effect on weal responses to BK.
Negative_regulation (reduced) of PAF associated with wheal and bradykinin
4) Confidence 0.42 Published 1996 Journal Clin. Exp. Dermatol. Section Abstract Doc Link 8689766 Disease Relevance 0.75 Pain Relevance 0.61
Significant desensitization of the PAF-induced [Ca2+]i mobilization responses was observed when the cells were treated repeatedly with PAF or mcPAF.
Negative_regulation (desensitization) of PAF-induced
5) Confidence 0.41 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2693427 Disease Relevance 0 Pain Relevance 0.22
Based on its blockade of PAF-activated PI turnover (Figure 1B), 10 µM PCA-42481 was expected to completely block the action of PAF or mcPAF in the HCECs.
Negative_regulation (blockade) of PAF-activated
6) Confidence 0.41 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2693427 Disease Relevance 0 Pain Relevance 0.22
We have shown that PAFR inhibition reduced the risk of NEC in a neonatal animal model using clinical risk factors for NEC (bacterial colonization, intestinal ischemia, and formula feeding) [5].
Negative_regulation (inhibition) of PAFR associated with neonatal necrotizing enterocolitis, cv general 4 under development and ischemia
7) Confidence 0.40 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955554 Disease Relevance 1.48 Pain Relevance 0.22
Neutrophil adherence to bladder microvascular endothelial cells following platelet-activating factor acetylhydrolase inhibition.
Negative_regulation (inhibition) of platelet-activating factor in platelet
8) Confidence 0.37 Published 2005 Journal J. Pharmacol. Exp. Ther. Section Title Doc Link 15937147 Disease Relevance 0.71 Pain Relevance 0.54
In contrast, a PAF antagonist and a neurokinin-1 receptor antagonist (ie, SP antagonist) significantly reduce supernatant-induced H2O2 production.
Negative_regulation (antagonist) of PAF associated with antagonist and substance p
9) Confidence 0.32 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2978390 Disease Relevance 0.28 Pain Relevance 0.73
In contrast, a PAF antagonist and a neurokinin-1 receptor antagonist (ie, SP antagonist) significantly reduce supernatant-induced H2O2 production.
Negative_regulation (antagonist) of PAF associated with antagonist and substance p
10) Confidence 0.32 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2978390 Disease Relevance 0.22 Pain Relevance 0.69
Since cellular immune infiltrate is a prerequisite for severe inflammation and tissue damage, inhibition of IL-8, SP and PAF-induced PBL migration and activation may provide potential targets for therapy.


Negative_regulation (inhibition) of PAF associated with inflammation and substance p
11) Confidence 0.31 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2978390 Disease Relevance 0.58 Pain Relevance 0.65
PAF levels remained elevated through the second (746.8 +/- 82.95), fourth (700.6 +/- 34.93) and sixth hours (644.4 +/- 42.85), and then decreased at the end of the attack, reaching levels significantly lower than those measured at the time of catheter insertion (565.5 +/- 38.34).
Negative_regulation (decreased) of PAF
12) Confidence 0.29 Published 2004 Journal Cephalalgia Section Abstract Doc Link 15265050 Disease Relevance 0.75 Pain Relevance 0.58
To investigate whether thromboxane and/or platelet activating factor (PAF) mediate the pulmonary vasoconstrictive response to antigen in vivo, we intra-arterially injected human erythrocytes as antigen into sensitized rabbits after administration of putative inhibitors: a cyclooxygenase synthetase inhibitor (indomethacin, 5 mg.kg-1), a thromboxane synthetase inhibitor (OKY 046, 10 mg.kg-1 + 100 micrograms.kg-1.min-1), and a PAF blocker (CV6209, .1 mg.kg-1).
Negative_regulation (blocker) of PAF in erythrocytes
13) Confidence 0.27 Published 1996 Journal Shock Section Abstract Doc Link 8885083 Disease Relevance 0.13 Pain Relevance 0
Indomethacin inhibited LTB4 and PAF synthesis whereas ketoprofen reduced degranulation.
Negative_regulation (inhibited) of PAF
14) Confidence 0.18 Published 1994 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 7708126 Disease Relevance 0.13 Pain Relevance 0.80
Out of the other NSAIDs, diclofenac (which is chemically related to fenamates) suppressed degranulation as well as LTB4 and PAF production.
Negative_regulation (suppressed) of PAF associated with cinod and diclofenac
15) Confidence 0.18 Published 1994 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 7708126 Disease Relevance 0.13 Pain Relevance 0.81
On the other hand, a small Japanese study did find a significant association between MS susceptibility and a PAFR polymorphism causing a modest but significant reduction of PAF-dependent signaling [190].
Negative_regulation (reduction) of PAF-dependent associated with multiple sclerosis
16) Confidence 0.18 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC2829540 Disease Relevance 1.06 Pain Relevance 0.53
Other processes described include inhibition of platelet activating factor and production of oxygen radicals and other anti-inflammatory factors (Egan et al 1999; Hanauer 2004).
Negative_regulation (inhibition) of platelet activating factor in platelet associated with inflammation
17) Confidence 0.03 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376091 Disease Relevance 0.55 Pain Relevance 0.27

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox